Évaluation des risques () < Évaluation préclinique de médicament < Évaluation préclinique de médicament ()

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by Évaluation préclinique de médicament

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]

Ident.	Authors (with country if any)	Title
000108 (2020)	David Cyranoski	This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan.
000316 (2020)	Manli Wang [République populaire de Chine] ; Ruiyuan Cao [République populaire de Chine] ; Leike Zhang [République populaire de Chine] ; Xinglou Yang [République populaire de Chine] ; Jia Liu [République populaire de Chine] ; Mingyue Xu [République populaire de Chine] ; Zhengli Shi [République populaire de Chine] ; Zhihong Hu [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Gengfu Xiao [République populaire de Chine]	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
000713 (2020)	Shibo Jiang	Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees.
000C95 (2018)	Rakhi Gawali [Inde] ; Jay Trivedi [Inde] ; Sujit Bhansali [Inde] ; Raghunath Bhosale [Inde] ; Dhiman Sarkar [Inde] ; Debashis Mitra [Inde]	Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
000D81 (2017)	Abdo A. Elfiky [Égypte] ; Samah M. Mahdy [Égypte] ; Wael M. Elshemey [Égypte]	Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.
001702 (2014)	Adeyemi O. Adedeji [États-Unis] ; Stefan G. Sarafianos [États-Unis]	Antiviral drugs specific for coronaviruses in preclinical development
001905 (2013)	Adriaan H. De Wilde [Pays-Bas] ; V. Stalin Raj [Pays-Bas] ; Diede Oudshoorn [Pays-Bas] ; Theo M. Bestebroer [Pays-Bas] ; Stefan Van Nieuwkoop [Pays-Bas] ; Ronald W. A. L. Limpens [Pays-Bas] ; Clara C. Posthuma [Pays-Bas] ; Yvonne Van Der Meer [Pays-Bas] ; Montserrat Bárcena [Pays-Bas] ; Bart L. Haagmans [Pays-Bas] ; Eric J. Snijder [Pays-Bas] ; Bernadette G. Van Den Hoogen [Pays-Bas]	MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment
002104 (2011)	So-Jung Park [Corée du Sud] ; Yang-Gyun Kim ; Hyun-Ju Park	Identification of RNA pseudoknot-binding ligand that inhibits the -1 ribosomal frameshifting of SARS-coronavirus by structure-based virtual screening.
002997 (2009)	Christopher Mcguigan [Royaume-Uni] ; Mary Rose Kelleher ; Plinio Perrone ; Sinead Mulready ; Giovanna Luoni ; Felice Daverio ; Sonal Rajyaguru ; Sophie Le Pogam ; Isabel Najera ; Joseph A. Martin ; Klaus Klumpp ; David B. Smith	The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479).
002A96 (2009)	Chih-Jung Kuo ; Hun-Ge Liu ; Yueh-Kuei Lo ; Churl-Min Seong ; Kee-In Lee ; Young-Sik Jung ; Po-Huang Liang	Individual and common inhibitors of coronavirus and picornavirus main proteases
003101 (2008)	Feng Ge [République populaire de Chine] ; Sheng Xiong ; Fu-Sen Lin ; Zhi-Ping Zhang ; Xian-En Zhang	High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery.
003104 (2008)	J D Huang [Hong Kong] ; B J Zheng ; H Z Sun	Helicases as antiviral drug targets.
003115 (2008)	Valerie Grum-Tokars [États-Unis] ; Kiira Ratia ; Adrian Begaye ; Susan C. Baker ; Andrew D. Mesecar	Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
003467 (2008)	Prasenjit Mukherjee [États-Unis] ; Prashant Desai [États-Unis] ; Larry Ross [États-Unis] ; E. Lucile White [États-Unis] ; Mitchell A. Avery [États-Unis]	Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits
003552 (2007)	S-Q Wang [République populaire de Chine] ; Q-S Du ; K. Zhao ; A-X Li ; D-Q Wei ; K-C Chou	Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy.
003A34 (2007)	William E. Severson [États-Unis] ; Nice Shindo ; Mindy Sosa [États-Unis] ; Thomas Fletcher [États-Unis] ; E. Lucile White [États-Unis] ; Subramaniam Ananthan [États-Unis] ; Colleen B. Jonsson [États-Unis]	Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its Application in Screening of a 100,000-Compound Library
003F24 (2006)	Pamela Hamill [Canada] ; Derek Hudson ; Richard Y. Kao ; Polly Chow ; Meera Raj ; Hongyan Xu ; Martin J. Richer ; François Jean	Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
004469 (2006)	Raymond H. See [Canada] ; Alexander N. Zakhartchouk [Canada] ; Martin Petric [Canada] ; David J. Lawrence [Canada] ; Catherine P. Y. Mok [Canada] ; Robert J. Hogan [États-Unis] ; Thomas Rowe [États-Unis] ; Lois A. Zitzow [États-Unis] ; Karuna P. Karunakaran [Canada] ; Mary M. Hilt [Canada] ; Frank L. Graham [Canada] ; Ludvik Prevec [Canada] ; James B. Mahony [Canada] ; Chetna Sharon [Canada] ; Thierry C. Auperin [Canada] ; James M. Rini [Canada] ; Aubrey J. Tingle [Canada] ; David W. Scheifele [Canada] ; Danuta M. Skowronski [Canada] ; David M. Patrick [Canada] ; Thomas G. Voss [États-Unis] ; Lorne A. Babiuk [Canada] ; Jack Gauldie [Canada] ; Rachel L. Roper [États-Unis] ; Robert C. Brunham [Canada] ; B. Brett Finlay [Canada]	Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
004864 (2005)	Nicholas A. Meanwell [États-Unis] ; Makonen Belema ; David J. Carini ; Stanley V. D'Andrea ; John F. Kadow ; Mark Krystal ; B Narasimhulu Naidu ; Alicia Regueiro-Ren ; Paul M. Scola ; Sing-Yuen Sit ; Michael A. Walker ; Tao Wang ; Kap-Sun Yeung	Developments in antiviral drug design, discovery and development in 2004.
004A94 (2005)	Bing Liu [République populaire de Chine] ; Jiaju Zhou [République populaire de Chine]	SARS‐CoV protease inhibitors design using virtual screening method from natural products libraries
004D64 (2005)	Alexander N. Zakhartchouk [Canada] ; Sathiyanarayanan Viswanathan [Canada] ; James B. Mahony [Canada] ; Jack Gauldie [Canada] ; Lorne A. Babiuk [Canada]	Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i -k "Évaluation préclinique de médicament" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i  \
                -Sk "Évaluation préclinique de médicament" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdFr.i
   |clé=    Évaluation préclinique de médicament
}}

---

This area was generated with Dilib version V0.6.33. Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021